Latest news with #SCAI
TECHx
3 days ago
- Business
- TECHx
MBZUAI and Sorbonne Partner on Artificial Intelligence
Home » Emerging technologies » Artificial Intelligence » MBZUAI and Sorbonne Partner on Artificial Intelligence Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) and Sorbonne University Abu Dhabi (SUAD) announced a strategic academic partnership to enhance collaboration in Artificial Intelligence (AI) research, education, and ethics. The Memorandum of Understanding (MoU) was signed yesterday at the MBZUAI campus by Professor Eric Xing, MBZUAI President, and Professor Nathalie Martial-Braz, SUAD Chancellor, in the presence of senior leaders from both universities. The partnership aims to support MBZUAI's vision of becoming a global center for AI innovation and research. It also aligns with SUAD's Center for Artificial Intelligence (SCAI), which operates from Abu Dhabi and Paris. Led by Professor Gérard Biau, SCAI contributes to advancing AI in Europe and the UAE and promotes interdisciplinary AI excellence. The MoU includes joint research initiatives focused on applying Artificial Intelligence across sectors such as healthcare, energy, climate science, transportation, and digital humanities. Both universities will co-supervise Ph.D. and postdoctoral researchers to help develop advanced AI talent. Faculty and researcher exchanges will promote interdisciplinary knowledge sharing and enhance education. The collaboration also plans to upskill professionals and youth through joint courses, workshops, and summer schools covering AI fundamentals, generative AI, and AI ethics. Professor Eric Xing said the partnership reflects a shared commitment to the responsible development of AI technology. He highlighted the goal of combining MBZUAI's research expertise with SUAD's interdisciplinary strengths to foster AI knowledge exchange between France and the UAE, focusing on the cultural applications of AI. Professor Nathalie Martial-Braz reported that this formal collaboration strengthens the UAE's AI ecosystem. She noted the partnership links two key research centers with the objective of advancing AI innovation and supporting the nation's economic and industrial growth. The agreement also calls for engagement with public and private sector partners to apply AI solutions to real-world challenges. Furthermore, the universities will contribute to ethical AI frameworks and data governance guidelines. Plans include producing white papers, best practices, and policy research to shape responsible AI use regionally and globally. Attending the signing from MBZUAI were Professor Sami Haddadin, Vice President for Research; Dekyi Liang, Vice President and Chief of Staff; and Joni Cholwich, Senior Advisor. From SUAD, attendees included Dr. Majed Al Khemeiri, Deputy Vice Chancellor for Administrative and Financial Affairs; Dr. Clio Chaveneau, Head of SAFIR Research Institute; and Manon Al Hakim, Chief of Staff. This MoU marks a significant step in uniting two of the UAE's leading AI institutions to combine expertise, empower talent, and position the UAE as a global hub for Artificial Intelligence innovation and transformation. Partnership supports UAE's national AI priorities in research and education Joint initiatives span healthcare, energy, climate, and transportation sectors Focus on ethical AI development, education, and cross-border collaboration
Business Insider
11-06-2025
- Business
- Business Insider
LEGENDARY HUMANITY, Announces Strategic Bitcoin Reserves and Enhancements to the VIVI Token Ecosystem
Singapore, Singapore, June 11th, 2025, Chainwire LEGENDARY HUMANITY PTE. LTD. (Headquarters: Singapore, CEO: Takamasa Suzuki) has announced today its asset management strategy utilizing Bitcoin (BTC). This initiative aims to stabilize the long-term value of the VIVI token ecosystem and enhance utility for token holders. This project bridges the gap between the real and digital worlds by integrating Web3 and digital fashion, leveraging AI-powered 3D scanning technology 'SCAI' for NFT authentication and fashion RWA. This announcement is part of a strategic initiative to enhance the financial stability and long-term sustainability of the project moving forward. Bitcoin Strategic Reserve Policy LEGENDARY HUMANITY will strategically accumulate Bitcoin (BTC) in stages using a portion of its internal funds. This Bitcoin initiative is not intended for the sale of financial products for asset management purposes, but rather as part of the project's autonomous financial strategy for the Web3 era. Quarterly Ecosystem Participation Rewards Point system and incentive exchange based on contributions to the project Enhancing the value of experiences within the ecosystem and providing new opportunities for participation Through this dual-pronged strategy of 'Bitcoin accumulation × token revenue distribution,' LEGENDARY HUMANITY aims to transcend the role of a mere digital fashion RWA project and serve as a 'fashion finance infrastructure' that fosters a cycle between fashion culture and RWA. This system is designed as part of the utility value associated with token ownership and is not intended to provide specific investment returns or principal guarantees. Main use cases and benefits of VIVI tokens: Digital fashion utility Early access to limited NFT collections 3D avatar customization features in metaverse spaces Discounts on virtual showroom rentals These features are made possible by SCAI's high-definition 3D scanning technology, enabling a digital asset experience. Access to physical × digital fusion events Based on the number of VIVI tokens held, the following benefits will be provided in stages through a tier system. Tier 1 (50,000 VIVI): Annual fashion event invitation (by lottery) Tier 2 (100,000 VIVI): Side event shipboard party invitation (by lottery) Tier 3 (200,000 VIVI): Rental rights for physical archive items The team prioritizes compliance with the legal frameworks of Singapore and other countries, collaborating with external law firms to strengthen our ongoing compliance framework. Moving forward, the team aims to continue striving for the establishment of a safe and sustainable token ecosystem, creating value through both technology and trust. LEGENDARY HUMANITY PTE. LTD. specializes in AI-powered 3D scanning technology called 'SCAI,' digitizing human-designed masterpieces and authenticating and storing them as NFTs. Our mission is to connect the value of precious assets to the future. Contact CSO Kenji Fujii
Indianapolis Star
04-06-2025
- General
- Indianapolis Star
Indiana high school softball all-state teams: Coaches pick IHSAA's top players
The Softball Coaches Association of Indiana announced its all-state honorees for the 2025 high school softball season. Players are divided into Class A/2A and 3A/4A, with first, second and third teams for each class. Teams were selected through a process organized by the SCAI. More: Meet the five finalists for 2025 Indiana Miss Softball
STV News
28-05-2025
- Politics
- STV News
Part-time sheriff dismissed over 'vulgar' comments attacking inquiry chair
A part-time sheriff who accused the chair of the Scottish Child Abuse Inquiry of being a 'monster', 'deranged' and 'evil' has been removed from office. John Halley, an author and member of the Faculty of Advocates, was appointed as junior counsel to the Scottish Child Abuse Inquiry (SCAI) in October 2015 but was dismissed in April 2019, and posted a series of social media posts regarding chair of the inquiry, Lady Smith. In 2020, he was investigated for 'misbehaviour' regarding Twitter posts and public statements between May 2019 and December 2019. A probe around 'unfitness for office by reason of misbehaviour', led by Judge Lord Bracadale, found that 'it is inappropriate for a judicial office holder to conduct a campaign against another member of the judiciary in such a confrontational and public way… Such conduct is improper and not consistent with the dignity of judicial office'. Mr Halley brought a case against Lady Smith in an employment tribunal in July 2019, alleging disability discrimination, but withdrew his claim in December, and the proceedings were dismissed that month. In a series of statements in May 2019 he alleged that from September 1 2016 he had to suffer disability discrimination, harassment and victimisation by Lady Smith and accused her of being 'a danger to cancer sufferers at work'; and less than a month later, he branded her a 'serious danger to cancer sufferers'. In December 2019, he repeated the allegations to a broadcaster. However, a ruling issued on Wednesday found Mr Halley had the option to follow a formal grievance process, and was expected to behave with 'dignity' in his role. Procedures around fitness for office were postponed until February 2023, following a judicial review. However in several months in 2023, Mr Halley again posted on Twitter criticising Lady Smith, including calling her 'deranged', a 'monster' and a 'bully', and sharing an excerpt of his book, A Judicial Monstering – Child Sexual Abuse Cover Up and Corruption in Scotland. Mr Halley claimed by raising a case at the employment tribunal he had the right to be protected from allegations of 'misbehaviour' and claimed the communications did not constitute this. However, he was dismissed from his role on the basis that his posts amounted to 'personal attacks' and became 'progressively worse over time'. A report said: 'The fundamental problem for the judicial office holder is that it is not possible to identify anything which might reasonably and properly be categorised as a protected disclosure of information as opposed to mere vulgar abuse and vituperation, repeatedly made in the most unprofessional of terms. 'There is therefore in the present case no risk of confusing any protected disclosure with the terms in which it is advanced.' It added that 'communications were not framed in the way one might expect from a professional judge, conscious of the dignity of the office, exercising appropriate restraint, and aware of the need to preserve public confidence; rather the tone was offensive, vulgar and confrontational. 'The communications certainly amounted to a public attack on the character and integrity of a fellow judge.' It continued: 'The communications referred to the chair of the inquiry as evil, corrupt, a monster, who had manufactured false criminal charges against him to get him arrested, and who was a bully who had treated him viciously, an abuser, a danger to cancer sufferers, evil and deranged, questioning whether she was a normal, compassionate, rational human being, and saying that she was a person who was guilty of the abuse of public funds. 'The tenor of the communications, and the language used, becomes progressively worse over time and it is not unreasonable to categorise it as a campaign of personal abuse addressed to the inquiry chair.' It said the messages 'are seriously lacking in dignity…. not simply rash or intemperate comments showing a one-off lack of judgment. They evidence a sustained lack of judgment over an extended period of time.' The report said Mr Halley had 'brought the office of sheriff into disrepute'. It added: 'We are satisfied that (Mr Halley) is unfit to hold office by reason of misbehaviour.' A statement from the Scottish Government said: 'Given the gravity of the tribunal's findings, the First Minister accepted there are compelling reasons to remove part-time Sheriff Halley and has taken that decision.' The SCAI has been contacted for comment. Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
Yahoo
22-05-2025
- Business
- Yahoo
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025
Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock Phase 3 program WARRINGTON, Pa., May 22, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ('Windtree' or the 'Company') (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue-generating company and advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it is targeting the planned interim analysis results for the istaroxime cardiogenic shock SEISMiC SCAI Stage C Phase 2 study (the 'SEISMiC C Study') for July 2025. The SEISMiC C Study is a global trial including sites in the U.S., Europe and Latin America. It is a placebo-controlled, double-blinded study with istaroxime being added to current standard of care, including inotropes or vasopressors. The effect of istaroxime in addition to these therapies will be assessed for six hours followed by the ability for istaroxime to allow reduction in the other inotropes and vasopressors based on the patient's condition. The primary endpoint of the study is the systolic blood pressure ('SBP') profile over the first six hours of treatment. Other key study measurements include various measures of cardiac function, SBP changes at specified timepoints, the vasopressor-inotrope score, avoidance of progression to SCAI Stage D or E cardiogenic shock and need for mechanical cardiac support, time to treatment failure, arrhythmia assessments, days alive and out of the hospital through day 30, physiologic measures (e.g., cardiac index) and length of stay in the intensive care unit and hospital. 'The interim data from the SEISMiC C Study are very important as we continue to evaluate the profile of istaroxime in more seriously ill patients with cardiogenic shock due to heart failure. The data from the first 20 patients will provide an initial assessment of the ability of istaroxime to show the same kind of physiological impact on top of standard of care to what has been seen in the previous studies in SCAI Stage B cardiogenic shock, as well as the emerging safety profile in this population,' said Dr. Steve Simonson, Chief Medical Officer and Senior Vice President of Windtree Therapeutics. 'Completion of the SEISMiC C Study is an important milestone to move steadily toward Phase 3 with istaroxime in cardiogenic shock.' About IstaroximeIstaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure demonstrate that istaroxime infused intravenously can significantly improve cardiac function and blood pressure without increasing heart rate or the incidence of clinically significant cardiac rhythm disturbances. About Windtree Therapeutics, Therapeutics, Inc. is a biotechnology company focused on becoming a revenue-generating company and advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree's portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking StatementsThis press release contains statements related to the potential benefits and safety of istaroxime; the clinical development of istaroxime; and our research and development program for treating patients in early cardiogenic shock due to heart failure. Such statements constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'proposed,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include, among other things: the Company could lose its deposit on the real estate property discussed above; the Company may fail to acquire such real estate property; the Company's ability to acquire revenue generating subsidiaries; the market's reaction to potential acquisitions by the Company; the Company's ability to secure significant additional capital as and when needed; the Company's ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company's other product candidates, including preclinical oncology candidates; the Company's ability to access the debt or equity markets; the Company's ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company's product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company's efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company's product candidates, if approved; the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People's Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company's operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company's ability to access the capital markets. These and other risks are described in the Company's periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information:Eric Curtisecurtis@
